Ladenburg Thalmann Financial Services Inc. grew its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 292.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 7,582 shares of the biopharmaceutical company’s stock after buying an additional 5,648 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Intercept Pharmaceuticals were worth $440,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WFG Advisors LP grew its stake in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the period. Aperio Group LLC acquired a new position in Intercept Pharmaceuticals in the second quarter valued at about $212,000. SG Americas Securities LLC acquired a new position in Intercept Pharmaceuticals in the second quarter valued at about $235,000. QCM Cayman Ltd. bought a new stake in shares of Intercept Pharmaceuticals in the second quarter valued at about $237,000. Finally, IFP Advisors Inc lifted its holdings in shares of Intercept Pharmaceuticals by 90.9% in the third quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares in the last quarter. 73.76% of the stock is owned by institutional investors.

A number of analysts have recently commented on the company. Citigroup restated a “neutral” rating and issued a $150.00 price target on shares of Intercept Pharmaceuticals in a report on Tuesday, September 19th. UBS Group lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, September 22nd. Cowen reissued a “buy” rating and set a $112.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Oppenheimer reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, October 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $141.58.

Shares of Intercept Pharmaceuticals Inc (NASDAQ ICPT) opened at $64.85 on Wednesday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals Inc has a 12 month low of $54.98 and a 12 month high of $135.59. The firm has a market capitalization of $1,575.91, a price-to-earnings ratio of -4.38 and a beta of -2.08.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The firm had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same period in the prior year, the company earned ($3.59) earnings per share. The company’s quarterly revenue was up 697.9% on a year-over-year basis. equities analysts anticipate that Intercept Pharmaceuticals Inc will post -13.35 EPS for the current fiscal year.

In other news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 2,566 shares of company stock valued at $151,025 over the last quarter. 4.50% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://theolympiareport.com/2017/12/27/ladenburg-thalmann-financial-services-inc-grows-stake-in-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.